WO2002003992A3 - Use of substituted indole compounds for treating prosthesis-related bone degeneration - Google Patents

Use of substituted indole compounds for treating prosthesis-related bone degeneration Download PDF

Info

Publication number
WO2002003992A3
WO2002003992A3 PCT/US2001/021084 US0121084W WO0203992A3 WO 2002003992 A3 WO2002003992 A3 WO 2002003992A3 US 0121084 W US0121084 W US 0121084W WO 0203992 A3 WO0203992 A3 WO 0203992A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
alkyl
prosthesis
formulae
substituted indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021084
Other languages
French (fr)
Other versions
WO2002003992A2 (en
Inventor
Simon Nicholas Jenkins
Barry Samuel Komm
Christopher Paul Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to AU2001271784A priority Critical patent/AU2001271784A1/en
Publication of WO2002003992A2 publication Critical patent/WO2002003992A2/en
Publication of WO2002003992A3 publication Critical patent/WO2002003992A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention comprises methods of treating bone prosthesis degeneration comprising administration of a compound of formulae (I) or (II), wherein Z is a moiety selected from the group of formulae (a, b or c), wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, or halogens; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH; Y is the moiety of formulae (d), R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof, and optionally an estrogen.
PCT/US2001/021084 2000-07-06 2001-06-29 Use of substituted indole compounds for treating prosthesis-related bone degeneration Ceased WO2002003992A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001271784A AU2001271784A1 (en) 2000-07-06 2001-06-29 Therapy for prosthesis-related bone degeneration

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21640700P 2000-07-06 2000-07-06
US21640600P 2000-07-06 2000-07-06
US60/216,406 2000-07-06
US60/216,407 2000-07-06

Publications (2)

Publication Number Publication Date
WO2002003992A2 WO2002003992A2 (en) 2002-01-17
WO2002003992A3 true WO2002003992A3 (en) 2002-06-27

Family

ID=26910981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021084 Ceased WO2002003992A2 (en) 2000-07-06 2001-06-29 Use of substituted indole compounds for treating prosthesis-related bone degeneration

Country Status (2)

Country Link
AU (1) AU2001271784A1 (en)
WO (1) WO2002003992A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG162615A1 (en) * 2002-06-13 2010-07-29 Wyeth Corp Bazedoxifene treatment regimens
WO2004039327A2 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
CN104643057A (en) 2002-07-24 2015-05-27 儿童医院医疗中心 Compositions and products containing s-equol, and methods for their making
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JO3112B1 (en) 2010-03-29 2017-09-20 Ferring Bv A fast dissolving pharmaceutical composition
NZ706991A (en) 2010-03-29 2016-08-26 Ferring Bv A fast dissolving pharmaceutical composition
KR20240142622A (en) 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
LT3386500T (en) 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
ES2990061T3 (en) 2016-05-10 2024-11-28 C4 Therapeutics Inc Spirocyclic degronimers for the degradation of target proteins
CN109641874A (en) 2016-05-10 2019-04-16 C4医药公司 C for target protein degradation3The glutarimide degron body of carbon connection
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (en) 2016-05-10 2019-05-21 C4医药公司 The C of amine connection for target protein degradation3Glutarimide degron body
RU2019102647A (en) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. PYRIMIDINE-BASED ANTIPROLIFERATING AGENTS
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
MX2019008158A (en) 2017-01-06 2019-12-09 G1 Therapeutics Inc Combination therapy for the treatment of cancer.
KR20190117582A (en) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. Benzothiophene Estrogen Receptor Modulator
CN110769822A (en) 2017-06-20 2020-02-07 C4医药公司 N/O-linked degron and degron bodies for protein degradation
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. MORPHIC FORMS OF GIT38 AND METHODS OF MAKING SAME
CN120698983A (en) 2018-12-20 2025-09-26 C4医药公司 Targeted protein degradation
KR20220034129A (en) 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 Estrogen receptor antagonist therapy
KR20220119415A (en) 2019-12-20 2022-08-29 씨4 테라퓨틱스, 인코포레이티드 Isoindolinone and indazole compounds for EGFR degradation
TW202146412A (en) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 Compounds for targeted degradation of brd9
IL300397A (en) 2020-08-05 2023-04-01 C4 Therapeutics Inc Compounds for targeted degradation of ret
MX2023014059A (en) 2021-06-08 2024-03-12 C4 Therapeutics Inc THERAPEUTIC FOR THE DEGRADATION OF A MUTANT SERINE/THREONINE PROTEIN KINASE.
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
EP4611901A1 (en) 2022-11-04 2025-09-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
EP4735452A2 (en) 2023-06-30 2026-05-06 Merck Patent GmbH Heterobifunctional compounds for the degradation of kras protein

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005824A1 (en) * 1994-08-22 1996-02-29 Eli Lilly And Company Methods for inhibiting bone prosthesis degeneration
EP0802184A1 (en) * 1996-04-19 1997-10-22 American Home Products Corporation N-Benzyl-2-phenylindoles as estrogenic agents
EP0802183A1 (en) * 1996-04-19 1997-10-22 American Home Products Corporation Estrogenic agents
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
WO1999059581A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens
WO1999059969A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
EP1123717A2 (en) * 2000-01-26 2001-08-16 Pfizer Products Inc. Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005824A1 (en) * 1994-08-22 1996-02-29 Eli Lilly And Company Methods for inhibiting bone prosthesis degeneration
EP0802184A1 (en) * 1996-04-19 1997-10-22 American Home Products Corporation N-Benzyl-2-phenylindoles as estrogenic agents
EP0802183A1 (en) * 1996-04-19 1997-10-22 American Home Products Corporation Estrogenic agents
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
WO1999059581A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens
WO1999059969A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
EP1123717A2 (en) * 2000-01-26 2001-08-16 Pfizer Products Inc. Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE DRUGNL [online] "TSE 424", XP002195073, retrieved from STN Database accession no. 2000:1286 *
R&D FOCUS DRUG NEWS, 17 April 2000 (2000-04-17) *

Also Published As

Publication number Publication date
AU2001271784A1 (en) 2002-01-21
WO2002003992A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
WO2002003992A3 (en) Use of substituted indole compounds for treating prosthesis-related bone degeneration
WO2002003986A3 (en) Use of substituted indole compounds for treating breast disorders
WO2002003976A3 (en) Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003991A3 (en) Use of substituted indole compounds for increasing nitric oxide synthase activity
WO2002003977A3 (en) Combinations of statins, estrogenic agents and optionally estrogens
WO2002003988A3 (en) Use of substituted indole compounds for treating neuropeptide y-related conditions
WO2002003990A3 (en) Use of substituted insole compounds for treating excessive intraocular pressure
WO2002003989A3 (en) Use of substituted indole compounds for treating sphincter incontinence
WO2002003987A3 (en) Pharmaceutical compositions of estrogenic agents
WO2002004418A3 (en) Methods of inhibiting uterotrophic effects of estrogenic agents
CO5550421A2 (en) INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASE
DK1299348T3 (en) Compounds and compositions for delivery of active agents
NO20024891L (en) Pharmaceutical compositions
CA2288910A1 (en) Pyrazolopyrimidinones for sexual dysfunction
EP1361220A4 (en) Cyclic compounds having thrombopoietin receptor agonism
CA2372560A1 (en) Cyanopyrroles for binding the progesterone receptor
MXPA05008364A (en) Pyrimidine derivatives for the prevention of hiv infection.
WO2000066614A8 (en) 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY
AU2001245972A1 (en) N-heterocyclic derivatives as nos inhibitors
EP1040823A3 (en) Stable foam compositions
HUP0402336A2 (en) Thieno[2,3-d]pyrimidine-2,4-dione derivatives, process for their preparation, their use in the modulation of autoimmune disease and pharmaceutical compositions containing them
UA74391C2 (en) Aryl- or heteroarylcondensed imidazoles as anti-inflammatory and analgesic agents
WO2001009103A3 (en) Imidazole antiproliferative agents
AP2001002302A0 (en) 13-Methyl erythromycin derivatives.
EP1057819A4 (en) Phthalazine derivatives and remedies for erectile dysfunction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP